This Executive Order instructs federal agencies to accelerate research, review, and potential approval pathways for psychedelic drugs intended to treat serious mental illnesses, including major depressive disorder and substance abuse disorder. The EO directs FDA to prioritize review of qualifying products with Breakthrough Therapy designation through the National Priority Voucher Program and to facilitate access to psychedelic drugs under the federal Right to Try Act. The EO tasks HHS to allocat...
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.